<DOC>
	<DOCNO>NCT01804361</DOCNO>
	<brief_summary>The purpose study determine efficacy safety Haporine-S eye drop patient moderate severe dry eye disease multicenter phase III clinical trial .</brief_summary>
	<brief_title>Efficacy Safety Study Haporine-S Treatment Moderate Severe Dry Eye Syndromes</brief_title>
	<detailed_description>This study compare efficacy safety topical Haposine-S RestasisÂ® eye drop 0.05 % patient moderate severe dry eye disease multicenter , investigator ( assessor ) blind , parallel design , non-inferiority phase III trial . Primary outcome change corneal stain score ( Oxford scheme ) 12 week baseline .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Male female , age 20 Patients moderate severe dry eye ( DEWS Level II ) Be inform nature study give write informed consent Being treat steroidal eye drop nonsteroidal antiinflammatory eye drop dry eye Being treat systemic steroid immunosuppressive History eyeball surgical operation within 6 month Wearing contact lenses participation study Pregnancy breastfeeding Use cyclosporine eye drop within 2 week Intraocular pressure ( IOP ) &gt; 25 mmHg History punctal occlusion within 1 month participation study Hypersensitivity investigational product suspicious Patients investigator considers inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Dry Eye Syndromes</keyword>
</DOC>